# US 2006/0052606 A1 · Factor xa Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0052606 A1
- Document ID: US20060052606A1
- Status: Published application
- Kind: A1
- Application number: 10/539,372
- Filed: 2003-12-22
- Published: 2006-03-09
- Earliest claimed: 2002-12-30
- Assignees: Eli Lilly and Company
- Inventors: Scott Sheehan; Brian Watson; John Liebeschuetz
- Web page: https://patentgrep.com/patent/US20060052606A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C07D 209/30: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D 211/22: by oxygen atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula (I) in which R1, n, Z, R3 and R4 have any of the meanings given in the specification, are inhibitors of the serine protease Factor Xa and are useful in the treatment of thrombotic disorders.

## Claims

### Claim 1

A compound of formula (I)
in which:—
R1 represents pyrrolidin-1-yl, piperidin-1-yl or a group of formula
in which X represents CH or N;
R2 represents a hydrogen atom or a (1-6C)alkyl, (3-6C)cycloalkyl, fluoro(1-4C)alkyl, fluoro(2-4C)alkanoyl, hydroxy(2-4C)alkyl or pyridyl group;
n represents 1, 2 or 3;
Z represents CH2, O or NR5, in which R5 represents a hydrogen atom or a (1-4C)alkyl group, provided that when R1 represents pyrrolidin-1-yl, piperidin-1-yl or a group of formula
and Z represents O or NR5, then n represents 2 or 3;
R3 represents:—
(i) phenyl which is unsubstituted or substituted by methylenedioxy or by a substituent selected from halogen, (1-4C)alkyl, hydroxy, (1-4C)alkoxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, (1-4C)alkylthio, (1-4C)alkylsulfinyl, (1-4C)alkylsulfonyl, carboxy, aminocarbonyl, amino, (2-4C)alkanoylamino, aminosulfonyl, (1-4C)alkylaminosulfonyl, nitro, phenyl, phenoxy, benzyloxy and pyridyl;
(ii) pyridyl, pyrimidyl or pyridazinyl, which is unsubstituted or substituted by a halogen atom;
(iii) furyl, thienyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, each of which is unsubstituted or substituted by (1-4C)alkyl or amino;
(iv) naphthyl, benzofuryl, benzothienyl, quinolyl or isoquinolyl;
(v) (3-6C)cycloalkyl; or
(vi) (1-4C)alkyl, which is unsubstituted or substituted by hydroxy, (1-4C)alkoxy, phenoxy, carboxy, aminocarbonyl, aminosulfonyl, (1-4C)alkylthio, phenylthio, pyridylthio, amino, (1-4C)alkylamino, di(1-4C)alkylamino, piperidin-1-yl, morpholino, trifluoromethyl, phenyl, imidazolyl, pyridyl, (3-6C)cycloalkyl, oxa(4-6C)cycloalkyl, or aza(4-6C)cycloalkyl (which may bear an N-(1-4C)alkyl substituent); and
R4 is selected from
in which
X1 represents a hydrogen atom, a halogen atom or an amino group;
X2 represents a hydrogen atom, a methyl group, a chlorine atom or a bromine atom;
X3 represents a hydrogen atom, a methyl group or a halogen atom;
X4 represents a chlorine atom, a methoxy group or a methyl group; and
X5 represents a hydrogen atom, a halogen atom or a methyl group;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound as claimed in claim 1, in which R1 represents a group of formula
in which X represents CH or N.

### Claim 3 (depends on 2)

A compound as claimed in claim 2, in which X represents CH.

### Claim 4 (depends on 2)

A compound as claimed in claim 2, in which R2 represents a (1-6C)alkyl, (3-6C)cycloalkyl, fluoro(1-4C)alkyl, fluoro(2-4C)alkanoyl, hydroxy(2-4C)alkyl or pyridyl group.

### Claim 5 (depends on 4)

A compound as claimed in claim 4, in which R2 represents a methyl, ethyl, isopropyl, cyclopropyl, cyclopentyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, trifluoroacetyl, 2-hydroxyethyl or pyrid-4-yl group.

### Claim 6 (depends on 5)

A compound as claimed in claim 5, in which R2 represents an isopropyl, cyclopropyl, cyclopentyl or pyrid-4-yl group.

### Claim 7 (depends on 1)

A compound as claimed in claim 1, in which n represents 1 or 2.

### Claim 8 (depends on 7)

A compound as claimed in claim 7, in which n represents 1.

### Claim 9 (depends on 1)

A compound as claimed claim 1, in which Z represents CH2.

### Claim 10 (depends on 1)

A compound as claimed in claim 1, in which Z represents O.

### Claim 11 (depends on 1)

A compound as claimed in claim 1, in which Z represents NR5.

### Claim 12 (depends on 11)

A compound as claimed in claim 11, in which R5 is hydrogen.

### Claim 13 (depends on 1)

A compound as claimed in claim 1, in which R3 represents:—
(i) phenyl, 2,3-methylenedioxyphenyl, 2-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 2-methylphenyl, 2-methoxyphenyl, 2-trifluoromethylphenyl, 2-difluoromethoxyphenyl, 4-carboxyphenyl or 4-aminocarbonylphenyl;
(ii) pyrid-2-yl or pyrid-4-yl;
(iii) fur-2-yl, fur-3-yl, thien-2-yl, thien-3-yl, imidazol-2-yl, thiazol-2-yl, thiazol-4-yl, 2-methylthiazol-4-yl or 2-aminothiazol-4-yl;
(iv) naphth-1-yl, naphth-2-yl, benzofuryl, benzothienyl, quinolin-4-yl or quinolin-8-yl;
(v) cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; or
(vi) methyl, ethyl, propyl, isopropyl, butyl, 2-methylpropyl, hydroxymethyl, 1-hydroxyethyl, methoxymethyl, 1-methoxyethyl, methylthiomethyl, 2-methylthioethyl, prop-2-ylthiomethyl, N,N-dimethylaminomethyl, phenylthiomethyl, pyrid-2-ylthiomethyl, carboxymethyl, 2-carboxyethyl, aminocarbonylmethyl, 2-aminocarbonylethyl, morpholinomethyl, 2,2,2-trifluoroethyl, benzyl, pyrid-2-ylmethyl, pyrid-3-ylmethyl, pyrid-4-ylmethyl, imidazol-1-ylmethyl, imidazol-4-ylmethyl, 3-methylimidazol-4-ylmethyl, cyclohexyl-4-ylmethyl, tetrahydropyran-4-ylmethyl, piperidin-1-ylmethyl or 1-methylpiperidin-4-ylmethyl.

### Claim 14 (depends on 13)

A compound as claimed in claim 13, in which R3 represents phenyl, 2-fluorophenyl or 2-chlorophenyl.

### Claim 15 (depends on 14)

A compound as claimed in claim 14, in which R3 represents phenyl.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A compound as claimed in claim 1, in which R4 is 4-chlorophenyl, 4-methoxyphenyl, indol-6-yl, 3-methylindol-6-yl, 3-chloroindol-6-yl, 5-chloroindol-2-yl or 6-chlorobenzo[b]thiophen-2-yl.

### Claim 19 (depends on 18)

A compound as claimed in claim 18, in which R4 is 4-methoxyphenyl, indol-6-yl or 5-chloroindol-2-yl.

### Claim 20 (depends on 1)

A pharmaceutical composition, which comprises a compound as claimed in claim 1, together with a pharmaceutically acceptable diluent or carrier.

### Claim 21 (depends on 1)

A process for preparing a compound as claimed in claim 1, which comprises
(a) reacting a compound of formula (II)
or a salt thereof, with a compound of formula (III)
HOOC—R4 (III)
or a reactive derivative thereof;
(b) for a compound of formula I in which R2 represents a (1-6C)alkyl, (3-6C)cycloalkyl, fluoro(1-4C)alkyl, fluoro(2-4C)alkanoyl or hydroxy(2-4C)alkyl, reacting a corresponding compound of formula (I) in which R2 represents a hydrogen atom, or a salt thereof, with an alkylating or acylating agent;
(c) for a compound of formula (I) in which Z represents NH, deprotecting a compound of formula
in which R6 represents an amino protecting group;
(d) for a compound of formula (I) in which R2 represents a hydrogen atom, deprotecting a compound of formula (I) in which R2 represents a protecting group;
followed, if a pharmaceutically acceptable salt is desired, by forming a pharmaceutically acceptable salt.

### Claim 22 (depends on 1)

A compound of formula (II)
or a salt thereof, in which R1, n, Z and R3 are as defined in claim 1.

### Claim 23 (depends on 1)

A compound of formula (IV)
a salt thereof, in which R6 represents an amino protecting group, and R1, R3 and R4 are as defined in claim 1.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 1)

A method of treating a thrombotic disorder in a mammal requiring treatment, which comprises administering an effective amount of a compound as claimed in claim 1.
